Effectiveness of COVID-19 booster vaccines against COVID-19-related symptoms, hospitalization and death in England.
Effectiveness of COVID-19 booster vaccines against COVID-19-related symptoms, hospitalization and death in England.
复制标题
DOI：
10.1038/s41591-022-01699-1
复制
发表时间：
2022-04
期刊：
影响因子：
82.9
通讯作者：
Bernal, Jamie Lopez
中科院分区：
文献类型：
--
作者：
Andrews, Nick;Stowe, Julia;Kirsebom, Freja;Toffa, Samuel;Sachdeva, Ruchira;Gower, Charlotte;Ramsay, Mary;Bernal, Jamie Lopez
从2021年9月14日开始，英国向成年人提供了信使RNA(MRNA)疫苗的加强免疫。我们使用试验阴性病例对照设计来评估加强剂量BNT162b2(辉瑞-BioNTech)与只接受两剂初级疗程(第二次接种后至少175天)或2021年9月13日至2021年12月5日未接种疫苗的个体相比的相对有效性，当时Delta变体在血液循环中占主导地位。结果是2019年有症状的冠状病毒病(新冠肺炎)和住院。以阿斯利康和BNT162b2为主要疗程的CHAdOx1-S(阿斯利康)和BNT162b2为主要疗程，BNT162b2或mRNA1273mR-NA强化免疫后14~34d对症状性疾病的相对有效率为85%~95%。疫苗的绝对有效率在94%到97%之间，在所有年龄组中都是相似的。在加强免疫后10周或更长时间，出现有限的消退。对于住院或死亡，BNT162b2增强剂在所有年龄组中的绝对有效率在所有年龄组中约为97%至99%，而不考虑初级疗程，最长10周内没有证据表明BNT162b2增强剂的效果减弱。这项研究提供了真实世界的证据，证明对轻度和严重疾病的强化疫苗剂量显著增加了保护作用，而不考虑初级疗程。对来自英国国家免疫管理系统的数据进行的一项检测阴性的病例对照分析表明，在接种CHAdOx1-S或BNT162b2疫苗的初级两剂疗程后，使用信使核糖核酸增强疫苗显著增强了对COVID住院或死亡的保护水平。
Booster vaccination with messenger RNA (mRNA) vaccines has been offered to adults in England starting on 14 September 2021. We used a test-negative case–control design to estimate the relative effectiveness of a booster dose of BNT162b2 (Pfizer-BioNTech) compared to only a two-dose primary course (at least 175 days after the second dose) or unvaccinated individuals from 13 September 2021 to 5 December 2021, when Delta variant was dominant in circulation. Outcomes were symptomatic coronavirus disease 2019 (COVID-19) and hospitalization. The relative effectiveness against symptomatic disease 14–34 days after a BNT162b2 or mRNA-1273 (Moderna) booster after a ChAdOx1-S (AstraZeneca) and BNT162b2 as a primary course ranged from around 85% to 95%. Absolute vaccine effectiveness ranged from 94% to 97% and was similar in all age groups. Limited waning was seen 10 or more weeks after the booster. Against hospitalization or death, absolute effectiveness of a BNT162b2 booster ranged from around 97% to 99% in all age groups irrespective of the primary course, with no evidence of waning up to 10 weeks. This study provides real-world evidence of substantially increased protection from the booster vaccine dose against mild and severe disease irrespective of the primary course. A test-negative case–control analysis of data from the National Immunisation Management System in England demonstrates significant levels of increased protection against hospitalization or death from COVID with mRNA booster vaccines following a primary two-dose course of either ChAdOx1-S or BNT162b2 vaccines.
登录
查看更多内容
DOI：
10.1016/s0140-6736(21)00677-2
发表时间：
2021-05-01
期刊：
Lancet (London, England)
影响因子：
--
作者：
Vasileiou E;Simpson CR;Shi T;Kerr S;Agrawal U;Akbari A;Bedston S;Beggs J;Bradley D;Chuter A;de Lusignan S;Docherty AB;Ford D;Hobbs FR;Joy M;Katikireddi SV;Marple J;McCowan C;McGagh D;McMenamin J;Moore E;Murray JL;Pan J;Ritchie L;Shah SA;Stock S;Torabi F;Tsang RS;Wood R;Woolhouse M;Robertson C;Sheikh A
通讯作者：
Sheikh A
DOI：
10.1016/s1473-3099(21)00330-3
发表时间：
2021-11
期刊：
The Lancet. Infectious diseases
影响因子：
--
作者：
Hyams C;Marlow R;Maseko Z;King J;Ward L;Fox K;Heath R;Tuner A;Friedrich Z;Morrison L;Ruffino G;Antico R;Adegbite D;Szasz-Benczur Z;Garcia Gonzalez M;Oliver J;Danon L;Finn A
通讯作者：
Finn A
DOI：
10.1056/nejmoa2114255
发表时间：
2021-10-07
期刊：
The New England journal of medicine
影响因子：
--
作者：
Bar-On YM;Goldberg Y;Mandel M;Bodenheimer O;Freedman L;Kalkstein N;Mizrahi B;Alroy-Preis S;Ash N;Milo R;Huppert A
通讯作者：
Huppert A
DOI：
10.1056/nejmoa2108891
发表时间：
2021-08-12
期刊：
The New England journal of medicine
影响因子：
--
作者：
Lopez Bernal J;Andrews N;Gower C;Gallagher E;Simmons R;Thelwall S;Stowe J;Tessier E;Groves N;Dabrera G;Myers R;Campbell CNJ;Amirthalingam G;Edmunds M;Zambon M;Brown KE;Hopkins S;Chand M;Ramsay M
通讯作者：
Ramsay M
影响因子：
16.6
作者：
Amirthalingam G;Bernal JL;Andrews NJ;Whitaker H;Gower C;Stowe J;Tessier E;Subbarao S;Ireland G;Baawuah F;Linley E;Warrener L;O'Brien M;Whillock C;Moss P;Ladhani SN;Brown KE;Ramsay ME
通讯作者：
Ramsay ME